La Zhang

Dr. La Zhang

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LZLa Zhang
La Zhang
JSJohannah Linda Shergis
Johannah Linda Shergis
LYLihong Yang
Lihong Yang
AZAnthony Lin Zhang
Anthony Lin Zhang
XGXinfeng Guo
Xinfeng Guo
CXCharlie Changli Xue
Charlie Changli Xue

1 April 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
LZLa Zhang
La Zhang
LYLihong Yang
Lihong Yang
JSJohannah Shergis
Johannah Shergis
LZLei Zhang
Lei Zhang
AZAnthony Lin Zhang
Anthony Lin Zhang
WMWei Mao
Wei Mao
Objectives: To provide a broad evaluation of the efficacy and safety of oral Chinese herbal medicine (CHM) as an adjunctive treatment for diabetic kidney disease (DKD), including mortality, progression to end-stage kidney disease (ESKD), albuminuria, proteinuria and kidney function.Design: A systematic review and meta-analysis.Methods: Randomised controlled trials (RCTs) comparing oral CHM with placebo as an additional intervention to conventional treatments were retrieved from five English (Cochrane Central Register of Controlled Trials, MEDLINE, Embase, Allied and Complementary Medicine Database and Cumulative Index of Nursing and Allied Health Literature) and four Chinese databases (China BioMedical Literature, China National Knowledge Infrastructure, Chonqing VIP and Wanfang) from inception to May 2018. RCTs recruiting adult DKD patients induced by primary diabetes were considered eligible, regardless of the form and ingredients of oral CHM. Mean difference (MD) or standardised mean difference (SMD) was used to analyse continuous variables and RR for dichotomous data.Results: From 7255 reports retrieved, 20 eligible studies involving 2719 DKD patients were included. CHM was associated with greater reduction of albuminuria than placebo, regardless of whether renin–angiotensin system (RAS) inhibitors were concurrently administered (SMD −0.56, 95% CI [−1.04 to –0.08], I2=64%, p=0.002) or not (SMD −0.92, 95% CI [−1.35 to –0.51], I2=87%, p<0.0001). When CHM was used as an adjunct to RAS inhibitors, estimated glomerular filtration rate was higher in the CHM than placebo group (MD 6.28 mL/min; 95% CI [2.42 to 10.14], I2=0%, p=0.001). The effects of CHM on progression to ESKD and mortality were uncertain due to low event rates. The reported adverse events in CHM group included digestive disorders, elevated liver enzyme level, infection, anaemia, hypertension and subarachnoid haemorrhage, but the report rates were low and similar to control groups. The favourable results of CHM should be balanced with the limitations of the included studies such as high heterogeneity, short follow-up periods, small numbers of clinical events and older patients with less advanced disease.Conclusions: Based on moderate to low quality evidence, CHM may have beneficial effects on renal function and albuminuria beyond that afforded by conventional treatment in adults with DKD. Further well-conducted, adequately powered trials with representative DKD populations are warranted to confirm the long-term effect of CHM, particularly on clinically relevant outcomes.PROSPERO registration number: CRD42015029293.

25 March 2015 in Nephrology
Verified
Journal Article
Closed access
PDF file
HLHui Liang
Hui Liang
XLXu‐Sheng Liu
Xu‐Sheng Liu
YWYu‐Chi Wu
Yu‐Chi Wu
LZLa Zhang
La Zhang
QLQi‐Zhan Lin
Qi‐Zhan Lin
YWYong‐Sheng Wang
Yong‐Sheng Wang

22 October 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
CYChangyuan Yang
Changyuan Yang
RDRuolan Duan
Ruolan Duan
ZYZhenhua Yang
Zhenhua Yang
JQJiamei Qiu
Jiamei Qiu
MPMinhui Pi
Minhui Pi
GSGuobin Su
Guobin Su
Introduction Physical inactivity is prevalent and associated with adverse outcomes among patients with chronic kidney disease (CKD). Most previous studies have relied on subjective questionnaires to assess levels of physical activity (PA) and mainly focused on patients undergoing dialysis. Therefore, the Physical Activity Elements and Adverse Outcomes in Patients with Chronic Kidney Disease in Guangdong study aims to investigate the levels and types of PA elements and their association with adverse outcomes in Chinese non-dialysis CKD (ND-CKD) patients. Methods and analysis In this prospective cohort study, 374 patients with ND-CKD will be recruited from Guangdong province, South of China. The primary exposure will be levels of PA assessed by ActiGraph GT3X+ accelerometer including the intensity, duration, frequency and type of PA. The traditional Chinese exercises such as tai chi and Baduanjin will also be assessed. The primary outcomes will be all-cause mortality. Other variables including demographics, comorbidities, medication and laboratory markers will be registered. All data will be updated annually for at least 5 years, or until the occurrence of death or initiation of renal replacement therapy. The Spearman correlation coefficient will be used to investigate the correlation between questionnaire-derived and accelerometry-derived PA. The Cox proportional hazards model will be used to investigate the association between level of PA and adverse outcomes. Non-linear associations between PA levels and outcomes, as well as the minimum desirable PA level, will be evaluated using restricted cubic splines. Ethics and dissemination The ethical permission for this study was obtained from the ethics committee of Guangdong Provincial Hospital of Chinese Medicine in Guangzhou, China (B2015-152-02). Written informed consent is obtained from all participants. The results will be disseminated by publication in a peer-reviewed journal and presented at relevant conferences.

7 August 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YYYu Yi
Yu Yi
YCYiqi Chen
Yiqi Chen
SFShulan Feng
Shulan Feng
FLFuhua Lu
Fuhua Lu
LZLa Zhang
La Zhang
Background: The impact of short-term atherogenic burden and long-term cumulative lipid exposure on the risk of incident T2DM with CKD remains unclear. This study examines the longitudinal associations between the Atherogenic Index of Plasma (AIP) and Cumulative Atherogenic Index of Plasma (CumAIP) with the development of T2DM complicated by CKD in middle-aged and older adults. Methods: A total of 5,779 participants from the CHARLS cohort were included. AIP and CumAIP were used to represent short-term and long-term lipid burdens, respectively. Multivariable logistic regression and restricted cubic spline models were applied to assess the dose-response relationships, adjusting for 11 conventional covariates. ROC curve analysis was conducted to evaluate predictive performance. An exploratory analysis further evaluated incident CKD among participants with T2DM at baseline (n = 494). Results: Both AIP and CumAIP were significantly associated with incident T2DM with CKD, with the highest quartiles showing modest but statistically significant associations with the outcome (AIP-Q4: OR: 1.013; 95% CI: 1.004–1.022; p < 0.05; CumAIP-Q4: OR: 1.017; 95% CI: 1.008–1.026; p < 0.001). Linear dose-response associations were observed across logistic regression and RCS regression models. ROC analysis showed that CumAIP demenstrated better discrimination than AIP (AUC 0.683 versus 0.650). In an exploratory analysis of participants with T2DM at the baseline (n = 494), both indices showed suggestive associations with incident CKD (AIP-Q4: OR: 1.050; 95% CI: 1.009–1.145; p = 0.025; CumAIP-Q4: OR: 1.081; 95% CI: 1.015–1.152; p = 0.016). Conclusion: AIP and CumAIP is significantly associated with incident T2DM with CKD among Chinese middle-aged and older adults. CumAIP demonstrated superior predictive performance over single AIP measurement. These findings support the potential value of long-term lipid monitoring for identifying indivuduals at increased risk of T2DM with CKD. An exploratory analyses also suggested a similar associations with progression from T2DM to CKD; however, these findings require confirmation in larger cohorts.

20 September 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
YCYiqi Chen
Yiqi Chen
XHXiaoxuan Hu
Xiaoxuan Hu
XLXiaoling Liang
Xiaoling Liang
WJWu Jianfeng
Wu Jianfeng
XXXiaoning Xie
Xiaoning Xie
LZLa Zhang
La Zhang
Objective: Fatigue is a highly prevalent and debilitating symptom among patients undergoing peritoneal dialysis (PD). Yet, feasible home-based interventions remain limited. To assess the feasibility and observed safety of home-based moxibustion in patients receiving PD and to explore the preliminary effects on fatigue. Methods: This single-center, waitlist-controlled randomized pilot trial was conducted at a tertiary hospital in Southern China from February to July 2023. Adults receiving maintenance PD with persistent fatigue and an overall Revised Piper Fatigue Scale (PFS-R) score of 4 or higher were randomly assigned at a 1:1 ratio to either a moxibustion or a waitlist control group. Participants in the intervention group received home-based moxibustion at the Shenque (CV8) acupoint at least 3 times per week for 12 weeks, in addition to standard PD care. Control participants received standard care alone during the trial and were offered delayed moxibustion supplies after completion of the last follow-up. The prespecified primary outcomes were the between-group difference in the mean overall PFS-R score at week 12 and the proportion of participants in the moxibustion group who achieved the target intervention dose. Additional outcomes included study retention, completion of scheduled study contacts, secondary clinical outcomes, and adverse events. Results: Of the 262 patients assessed for eligibility, 44 met the eligibility criteria, of whom 25 declined participation for personal reasons, and 19 were randomized (mean [SD] age, 47.5 [12.4] years; 16 [84.2%] women). All completed the 12-week follow-up. All 57 scheduled on-site visits and 56 of 57 telephone follow-ups (98.2%) were completed. Eight of nine participants in the moxibustion group achieved the target intervention dose (88.9%; 95% CI, 51.8–99.7%). The exploratory fatigue findings were inconsistent. In the exploratory week-12 comparison, the mean PFS-R score was lower in the moxibustion group than in the control group (unadjusted mean difference, −1.09 points; 95% CI, −2.15 to −0.03; p = 0.04). However, the between-group difference in change from baseline was −0.36 points (95% CI, −2.03 to 1.31; p = 0.65), and no group-by-time interaction was observed (p = 0.86). Other clinical outcomes showed no consistent between-group differences. Adverse events occurred in four of nine participants in the moxibustion group and two of ten in the control group. No serious adverse events or permanent intervention discontinuations occurred. Conclusions and Relevance: Among selected randomized participants, a 12-week home-based moxibustion intervention supported by standardized training and follow-up was delivered with high adherence and complete retention. However, the low screening-to-randomization proportion limits conclusions about recruitment feasibility and broader implementation, and the exploratory findings do not establish efficacy or provide definitive evidence of safety. Further evaluation in a larger, sham-controlled trial is warranted.